Citi analyst Geoff Meacham raised the firm’s price target on Kiniksa (KNSA) to $50 from $45 and keeps a Buy rating on the shares as part of a Q3 preview for the biotechnology group. The firm believes investor interest in the smaller cap biotech names is building, which could set the group up well for 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA:
- Kiniksa granted orphan designation for treatment of pericarditis
- Kiniksa price target raised to $44 from $38 at Wedbush
- Kiniksa Pharmaceuticals: Strong Buy Rating Driven by Arcalyst’s Market Success and Promising Pipeline
- Kiniksa initiated with a Buy at TD Cowen
- Kiniksa Pharmaceuticals Highlights Cardiovascular Focus and Growth